1 / 13

ANTI-TUMOR EFFECTS OF AN IMIDAZOQUINOLINE IN RENAL CELL CARCINOMA

ANTI-TUMOR EFFECTS OF AN IMIDAZOQUINOLINE IN RENAL CELL CARCINOMA. Michael Schwartz, MD 3/14/2007. What are imidazoquinolines?. Family of immune response modifiers of which imiquimod is the most commonly used.

noelle-richardson
Télécharger la présentation

ANTI-TUMOR EFFECTS OF AN IMIDAZOQUINOLINE IN RENAL CELL CARCINOMA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANTI-TUMOR EFFECTSOF AN IMIDAZOQUINOLINE IN RENAL CELL CARCINOMA Michael Schwartz, MD 3/14/2007

  2. What are imidazoquinolines? • Family of immune response modifiers of which imiquimod is the most commonly used. • Act on Toll-like receptors which can increase cellular production of TNF, IFN-, and a variety of other cytokines. • Shown to improve antigen presentation by dendritic cells • Imiquimod is FDA approved for topical treatment of genital condyloma and basal cell carcinoma.

  3. Project Background • Renal cell carcinoma (RCC) responds to immunomodulators (IL-2, IFN-) • Imiquimod has been used as an immune response modifier in basal cell carcinoma • We hypothesized that imidazoquinolines may have direct in vitro and in vivo biological activity against renal cell carcinoma.

  4. Study Design • 4 renal cell carcinoma cell lines used • 1 mouse (RENCA) • 3 human (CAKI-1, CAKI-2, A-498) Experimental drug: 3M-011 • Closely related to Imiquimod (3M Pharmaceuticals) • Potential for use as an oral agent

  5. Do renal cell carcinoma cell lines express Toll-like receptor 7?

  6. Can 3M-011 affect cell viability? • Evaluated by cell counts • Cells cultured in with media supplemented with 3M-011at 100 g/ml • Cells harvested and counted at 24, 48, and 72 hour time points

  7. Potential correlation between cell viability and level of TLR-7 expression

  8. Figure 2

  9. In vivo affects of 3M-011 on a murine metastatic RCC model

  10. In vivo results • 30% of mice in 3M-011 group showed no pathologic evidence of tumor

  11. 3M-011 PLACEBO

  12. Summary and Conclusions • TLR-7 is expressed in both murine and human renal cancer cell lines. • Imidazoquinolines have direct biological effects on renal cell carcinoma cell lines by decreasing cell viability and inducing apoptosis. • Our results suggest a potential correlation between the TLR-7 expression level and the effect of 3M-011 on cell viability. • Initial results in an immune competent mouse model of metastatic renal cell carcinoma suggest anti-tumor effects in vivo.

  13. Jemal A, Siegel R, Ward E, Murray T Xu J, , Murray T, Smigel C, Thun M. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Cur Urol Rep 2005;6:7-18. Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 2003;30:601-609. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon-2b compared with interferon-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659. Medical Research Council Renal Cancer Collaborators. Interferon- and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14-17. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-2867. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003;23:4369-76. Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003;50:9-24. Cook DN, Pisetcky DS, Schwartz, DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5:975-9. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70:2335-42. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol. 2002;41:810-6. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, and Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Can Res 2004;10:8648-55. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;505:722-33. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-8. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schon MP. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49. Schon MP, Wienrich BG, Drewniok C, Bong AB, Gollnick H, Schon M, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004;122:1266-1276. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis. 2004;9:291-8. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86. Imbertson LM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110:734-9. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993;53:5176-80. References

More Related